US20230098128A1 - Devices and methods for lateral flow tests of bodily fluids - Google Patents
Devices and methods for lateral flow tests of bodily fluids Download PDFInfo
- Publication number
- US20230098128A1 US20230098128A1 US18/077,242 US202218077242A US2023098128A1 US 20230098128 A1 US20230098128 A1 US 20230098128A1 US 202218077242 A US202218077242 A US 202218077242A US 2023098128 A1 US2023098128 A1 US 2023098128A1
- Authority
- US
- United States
- Prior art keywords
- receptacle
- bodily fluids
- lateral flow
- test strip
- fluid volume
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 178
- 238000012125 lateral flow test Methods 0.000 title claims abstract description 101
- 238000000034 method Methods 0.000 title abstract description 19
- 238000012360 testing method Methods 0.000 claims abstract description 122
- 239000012530 fluid Substances 0.000 claims abstract description 75
- 239000002250 absorbent Substances 0.000 claims description 8
- 230000002745 absorbent Effects 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 2
- 239000012491 analyte Substances 0.000 description 39
- 239000013076 target substance Substances 0.000 description 34
- 238000000502 dialysis Methods 0.000 description 18
- 238000012546 transfer Methods 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 14
- 206010034674 peritonitis Diseases 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 238000004820 blood count Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061138 Fungal peritonitis Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010051335 Lipocalin-2 Proteins 0.000 description 1
- 102000013519 Lipocalin-2 Human genes 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0605—Metering of fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0621—Control of the sequence of chambers filled or emptied
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0478—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
- B01L2400/0644—Valves, specific forms thereof with moving parts rotary valves
Definitions
- Peritonitis is a major cause of morbidity and mortality in peritoneal dialysis (“PD”) patients globally.
- PD peritoneal dialysis
- peritonitis can be diagnosed when at least two of the following are present: (1) clinical features consistent with peritonitis, e.g., abdominal pain and/or cloudy dialysis effluent; (2) dialysis effluent with a white blood cell count greater than 100/ ⁇ L or greater than 0.1 ⁇ 109/L (after a dwell time of at least two hours), with more than 50% of the white blood counts being polymorphonuclear; and (3) a positive peritoneal dialysis effluent culture.
- Such therapy typically includes administering at least two different broad-spectrum antibiotics which collectively cover most of the gram-positive and gram-negative bacteria, along with an anti-fungal agent to prevent secondary fungal peritonitis until the causative agent(s) and drug susceptibility tests become available.
- lateral flow tests also commonly referred to as “lateral flow assays” to diagnose peritonitis or other conditions have been developed.
- a lateral flow test for peritonitis or other conditions are performed by placing a bodily fluid (also referred to as an “analyte”) that may contain a target substance functioning as a marker for the condition on an end of a prepared test strip, laying the test strip on a horizontal surface, and allowing the analyte to wick across the test strip via capillary action.
- a target substance also referred to as an “analyte”
- bioactive particles also referred to as “conjugates”
- the combined target substance and bioactive particles congregate at a test line, and an indication (e.g., a color) of the presence of the target substance appears. If there is not enough (e.g., none) of the target substance in the analyte, then the indication does not appear at the test line or the indication is faint. Regardless of whether enough of the target substance is present in the analyte, a control indication may appear at a control line when the fluid reaches the control line, to indicate that the test was successfully completed.
- an indication e.g., a color
- the fluid may not reach the control line, and no control indication will appear at the control line. Without a control indication appearing, another test may be required. If too much analyte is applied, the test may show a false positive. Additionally or alternatively, too much analyte may result in an oversaturated test strip and/or spills, which can present a hazard particularly when the analyte is a bodily fluid.
- FIGS. 1 A- 1 C are perspective diagrams of a device for lateral flow testing of bodily fluids at various stages of operation, according to at least one embodiment of the present disclosure.
- FIG. 2 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure.
- FIG. 3 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure.
- FIG. 4 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure.
- FIG. 5 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure.
- FIG. 6 is a flow chart illustrating a method of lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure.
- FIG. 7 A is a perspective view of a device for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure.
- FIG. 7 B is a cross-sectional side view of the device of FIG. 7 A , taken at line A-A of FIG. 7 A .
- FIG. 8 is a flow chart illustrating a method of lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure.
- the present disclosure is generally directed to devices and methods for lateral flow testing of bodily fluids, such as for peritonitis.
- such devices may be configured to apply a predetermined, appropriate volume of a bodily fluid on a lateral flow test strip.
- the device may include a first receptacle for receiving bodily fluids from a patient and a second receptacle configured to receive bodily fluids from the first receptacle.
- the first receptacle may include a first, relatively larger volume
- the second receptacle may include a second volume that is predetermined for application to one or more lateral flow test strips.
- the device may include a receptacle for receiving bodily fluids from a patient.
- the receptacle may have a predetermined fluid volume that is selected to be applied to at least one lateral flow test strip.
- An overflow chamber may be configured for receiving the bodily fluids in excess of the predetermined fluid volume (e.g., that may overflow from the receptacle).
- these and other example embodiments may enable the application of an appropriate amount of bodily fluid analyte on the lateral flow test strip(s), without additional complexity for the user.
- the devices of the present disclosure may receive an excess of bodily fluids without the user needing to precisely measure the amount applied or without needing to time the exposure of the test strip to the fluid.
- the device may automatically apply the appropriate amount of the analyte to the lateral flow test strip(s).
- FIGS. 1 A- 5 , 7 A, and 7 B detailed descriptions of devices for lateral flow testing of bodily fluids or other analytes, according to various embodiments of the present disclosure.
- FIGS. 6 and 8 the following will provide detailed descriptions of methods for lateral flow testing of bodily fluids, according to additional embodiments of the present disclosure.
- FIGS. 1 A- 1 C are perspective diagrams of a device 100 for lateral flow testing of bodily fluids at various stages of operation, according to at least one embodiment of the present disclosure.
- the device 100 may include a receptacle 102 for an analyte 104 from a patient (e.g., a peritoneal dialysis patient) for testing for the presence of a marker for a condition (e.g., peritonitis).
- a lateral flow test strip 106 may be positioned for receiving the analyte 104 from the receptacle 102 in a well portion 108 .
- the lateral flow test strip 106 may also include a conjugate pad 110 , a membrane 112 , a test line 114 , a control line 116 , and an absorbent pad 118 .
- the receptacle 102 may have a size and shape to hold a predetermined volume of the analyte 104 for application of an appropriate amount of the analyte 104 to the lateral flow test strip 106 . Any analyte 104 in excess of the predetermined volume may be kept away (e.g., diverted away, held in another receptacle, etc.) from the lateral flow test strip 106 . Some suitable examples for keeping excess analyte 104 away from the lateral flow test strip 106 are described below with reference to FIGS. 2 - 5 , 7 A, and 7 B .
- the analyte 104 may be a bodily fluid or any other fluid to be tested for the detection and/or quantification of a target substance 120 that may be in the analyte 104 .
- the analyte 104 may be or include a sample of blood, urine, saliva, effluent from a peritoneal dialysis treatment, etc., from a patient.
- the target substance 120 may be a marker for a condition, such as peritonitis, a pathogen, pregnancy, etc.
- the target substance 120 may be or include an antibody, a protein, a hormone, an antigen, bacteria, a fungus, etc.
- the well portion 108 may be an adsorbent pad configured to receive the analyte 104 and to prepare the analyte 104 (e.g., via a surfactant, buffer salt, etc.) for analysis by the lateral flow test strip 106 .
- the conjugate pad 110 may contain conjugates 122 (e.g., bioactive particles, such as antibodies) that may be reactive specifically to the target substance 120 .
- conjugates 122 e.g., bioactive particles, such as antibodies
- the conjugates 122 may include detectable particles, such as gold or latex microspheres for visual detection. Other detectable particles may also be used, such as fluorescent particles and/or magnetic particles.
- the conjugates 122 may be maintained in a functionally stable state prior to use, such as by coating the conjugates 122 in a water-soluble material, such as sucrose.
- the sucrose or other coating may dissolve into water of the analyte 104 , exposing and chemically activating the conjugates 122 for reaction (e.g., for chemically binding) with the target substance 120 .
- the membrane 112 may be configured to further convey the analyte 104 along the lateral flow test strip 106 , such as by capillary action.
- the membrane may include, for example, a cellulose material or other porous material configured to convey the analyte 104 along the lateral flow test strip 106 .
- the test line 114 may be a region of the membrane 112 with immobilized anti-analyte particles 124 , which may be selected to react with particles of the target substance 120 that have been bound to the conjugates 122 . As illustrated in FIG. 1 C , the bound target substance 120 and conjugates 122 may react with the anti-analyte particles 124 and may congregate along the test line 114 . When the target substance 120 is present in the analyte 104 in sufficient quantities, a detectable signal may be produced along the test line 114 .
- a visible color e.g., from colored particles of the conjugates 122
- fluorescent line e.g., fluorescent line
- magnetic line e.g., magnetic line
- the control line 116 may be a region of the membrane 112 with immobilized anti-conjugate particles 126 , which may be selected to react with the conjugates 122 . As illustrated in FIG. 1 C , the conjugates 122 may react with the anti-conjugate particles 126 and may congregate along the control line 116 . This may provide an indication that the lateral flow test strip 106 has successfully conveyed the analyte 104 across the test line 114 , regardless of whether there is enough of the target substance 120 in the analyte 104 to form a positive indication on the test line 114 . Thus, after the control line 116 indicates that the test has been completed, the test line 114 may be analyzed for a positive or negative result.
- any additional analyte 104 may be conveyed past the control line 116 to the absorbent pad 118 .
- the absorbent pad 118 may be a sponge or other porous material configured to soak up and contain additional analyte 104 .
- lateral flow testing concepts will next be described. These lateral flow testing concepts may be combined with the device 100 and related concepts as described above. Other concepts known to those skilled in the art of lateral flow testing may also be used.
- the antigen indicative of an inflammatory response in the peritoneum may be neutrophil gelatinase-associated lipocalin, interleukin 1, interleukin 6, interleukin 8, tumor necrosis factor ⁇ , procalcitonin, and/or C-reactive protein.
- Lipoteichoic acid is an antigen indicative of the presence of gram-positive bacteria.
- Lipopolysaccharide is an antigen indicative of the presence of gram-negative bacteria.
- ⁇ -glucan is an antigen indicative of the presence of a fungus.
- the pathogen may be at least one bacterium and/or fungus.
- the conjugates 122 may include a binding molecule that specifically binds an antigen indicative of the presence of a specific pathogen species.
- the specific pathogen may be Staphylococcus aureus, Pseudomonas sp., Staphylococcus epidermidis, Staphylococcus haemolyticus, Candida sp., Escherichia coli , vancomycin-resistant enterococci, or combinations thereof.
- the lateral flow test strip 106 may include a buffer that specifically elutes antigen(s), such as in the well portion 108 of the lateral flow test strip 106 .
- the buffer composition may be chosen to selectively stabilize the antigen and/or antigen-antibody complex, maintain pH, and/or maintain or disrupt structure or binding of the antigen-antibody complex.
- the device 100 may be used to diagnose peritonitis in a patient by detecting, in a peritoneal dialysis effluent analyte, an antigen indicative of an inflammatory response having been launched in the peritoneum, detecting an antigen indicative of the presence of a gram-positive bacteria, detecting an antigen indicative of the presence of a gram-negative bacteria, and/or detecting an antigen indicative of the presence of a fungus.
- the analyte 104 may include a peritoneal dialysis effluent that is taken directly from the patient and applied to the device 100 , or the peritoneal dialysis effluent may be concentrated, filtered, and/or enriched prior to application to the device 100 .
- enrichment may be by, for example, placing the peritoneal dialysis effluent sample into a conical tube, followed by centrifugation of the sample, and treatment with, e.g., a lysis buffer, extraction buffer, and/or neutralization buffer.
- Enrichment of a peritoneal dialysis effluent sample for antigens may also be by use of an ultrafiltration (“UF”) membrane (e.g., molecular weight cutoff 29 , 000 ).
- UF ultrafiltration
- a syringe may be used to pass/push the peritoneal dialysis effluent sample through a UF membrane instead of using a centrifuge.
- Such diagnostic methods can be used to treat peritonitis in the patient by first diagnosing the patient as having peritonitis and then administering an appropriate antibiotic to the subject to treat the peritonitis in view of the diagnosis.
- FIGS. 1 A- 1 C may be employed in conjunction with any of the examples discussed below with reference to FIGS. 2 - 8 .
- FIG. 2 is a cross-sectional side view of a device 200 for lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure.
- the device 200 may include a first receptacle 202 for receiving bodily fluids from a patient and a second receptacle 204 positioned for receiving a portion of the bodily fluids from the first receptacle 202 .
- a test strip holder 206 may be positioned under the second receptacle 204 to receive the bodily fluids from the second receptacle 204 .
- the first receptacle 202 may have a first fluid volume, which may be larger than is needed to perform a successful lateral flow test.
- the second receptacle 204 may have a predetermined second fluid volume that is selected to be applied to at least one lateral flow test strip 208 inserted in the test strip holder 206 .
- the second fluid volume may be selected to apply a sufficient amount of the bodily fluids to the at least one lateral flow test strip 208 for a complete and successful test, but not so much that the lateral flow test strip(s) 208 become oversaturated.
- relational terms such as “first,” “second,” “upper,” “below,” etc., may be used for clarity and convenience in understanding the disclosure and accompanying drawings and may not necessarily connote or depend on any specific preference, orientation, or order, except where the context clearly indicates otherwise.
- the device 200 may also include a transfer mechanism 210 to move the bodily fluid from the second receptacle 204 to the test strip holder 206 and ultimately to the at least one lateral flow test strip 208 .
- the transfer mechanism 210 may include a rotating piston 212 that may be configured to rotate the second receptacle 204 from a first position (shown in FIG. 2 in solid lines) for receiving the bodily fluid from the first receptacle 202 to a second position (shown in FIG. 2 in dashed lines) for transferring (e.g., via gravity) the bodily fluid from the second receptacle 204 to the test strip holder 206 .
- the rotating piston 212 may be biased (e.g., spring-biased) to the first position, such as to avoid inadvertent spilling of bodily fluids through the second receptacle 204 and test strip holder 206 .
- the rotating piston 212 may include a knob 214 to enable a user to grasp and rotate the rotating piston 212 into the second position after the bodily fluids are positioned in the first receptacle 202 and allowed to flow into the second receptacle 204 .
- the first receptacle 204 may include a lid 216 for covering the first receptacle 204 .
- the lid 216 may be configured to provide a fluid-tight seal (e.g., via an O-ring and a clasp 218 ), which may reduce or eliminate a chance of spilling the bodily fluids within the first receptacle 204 when the lid 216 is closed.
- the test strip holder 206 may be removable and replaceable relative to the first receptacle 202 and second receptacle 204 .
- the test strip holder 206 may be used with the first receptacle 202 and second receptacle 204 to test bodily fluids positioned within the first receptacle 202 , and then the test strip holder 206 with its lateral flow test strip(s) 208 may be decoupled from the first receptacle 202 and second receptacle 204 .
- a replacement test strip holder 206 with one or more unused lateral flow test strip(s) 208 may be coupled to the first receptacle 202 and second receptacle 204 to run another test on the bodily fluids within the first receptacle 202 .
- multiple tests may be sequentially performed on the bodily fluids within the first receptacle 202 , without the need for obtaining a new sample from the patient for each test.
- a user may place bodily fluids to be tested within the first receptacle 202 and the lid 216 may be closed.
- the lateral flow test strip(s) 208 that are configured to detect one or more target substances may be positioned at least partially within the test strip holder 206 .
- a portion of the bodily fluids may be allowed flow into the second receptacle 204 .
- the user may rotate the knob 214 to transfer the predetermined second volume of the bodily fluids from the second receptacle 204 to the lateral flow test strip(s) 208 .
- the bodily fluids may be conveyed along the lateral flow test strip(s) 208 and tested for the presence and/or quantity of the target substance(s), as described above with reference to FIGS.
- the lateral flow test strip(s) 208 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids.
- the device 200 including any excess bodily fluids that may remain within the first receptacle 202 , may be discarded, such as in an appropriate biohazard waste container.
- FIG. 3 is a cross-sectional side view of a device 300 for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure.
- the device 300 may be similar to the device 200 described above with reference to FIG. 2 .
- the device 300 may include a first receptacle 302 having a first fluid volume, a second receptacle 304 having a predetermined second fluid volume for application to one or more lateral flow test strips 308 , a test strip holder 306 for holding the lateral flow test strip(s) 308 , and a transfer mechanism 310 for transferring the second fluid volume of the bodily fluids from the second receptacle 304 to the lateral flow test strip(s) 308 in the test strip holder 306 .
- the first receptacle 302 may include a lid 316 , such as to avoid spills of the bodily fluids from the first receptacle 302 .
- the transfer mechanism 310 may include a syringe 320 positioned and configured to withdraw the second fluid volume of the bodily fluids from the first receptacle 302 .
- the second receptacle 304 may be defined by an internal volume of the syringe 320 when a plunger of the syringe 320 is fully withdrawn.
- a first one-way channel 322 e.g., a first check valve
- the first one-way channel 322 may be configured to let fluid flow from the first receptacle 302 into the second receptacle 304 , but may inhibit (e.g., prevent) the flow of fluid from the second receptacle 304 back into the first receptacle 304 .
- a second one-way channel 324 (e.g., a second check valve) may be positioned between the second receptacle 304 and the test strip holder 306 .
- the second one-way channel 324 may be configured to let fluid flow from the second receptacle 304 into the test strip holder 306 , but may inhibit (e.g., prevent) the flow of fluid from the test strip holder 306 into the second receptacle 304 .
- the syringe 320 may include a knob 326 for a user to grasp the syringe 320 to operate the device 300 .
- the syringe 320 may be mounted to a pivot 328 .
- the second receptacle 304 may be in fluid communication with the first receptacle 302 when the syringe 320 and pivot 328 are in a first position (shown in FIG. 3 ).
- the syringe 320 may be rotated about the pivot 328 (e.g., in a counterclockwise direction from the perspective of FIG. 3 ) to orient the syringe 320 such that the second receptacle 304 is in fluid communication with the test strip holder 306 .
- a user may place bodily fluids to be tested within the first receptacle 302 and the lid 316 may be closed.
- the lateral flow test strip(s) 308 that are configured to detect one or more target substances may be positioned at least partially within the test strip holder 306 .
- the user may grasp and pull the knob 326 to draw the second fluid volume of the bodily fluids with the syringe 320 from the first receptacle 302 through the first one-way channel 322 and into the second receptacle 304 .
- the syringe 320 is mounted to the pivot 328 , the user may rotate the syringe 320 using the pivot from the first position to the second position.
- the user may then push on the knob 326 to force the second fluid volume of the bodily fluids from the second receptacle 304 into the test strip holder 306 and ultimately onto the lateral flow test strip(s) 308 .
- the bodily fluids may be tested for the presence and/or quantity of the target substance(s), as described above with reference to FIGS. 1 A- 1 C .
- the lateral flow test strip(s) 308 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids.
- the device 300 including any excess bodily fluids that may remain within the first receptacle 302 , may be discarded, such as in an appropriate biohazard waste container.
- FIG. 4 is a cross-sectional side view of a device 400 for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure.
- the device 400 may be similar to the device 200 described above with reference to FIG. 2 .
- the device 400 may include a first receptacle 402 having a first fluid volume, a second receptacle 404 having a predetermined second fluid volume for application to one or more lateral flow test strips 408 , a test strip holder 406 for holding the lateral flow test strip(s) 408 , and a transfer mechanism 410 for transferring the second fluid volume of the bodily fluids from the second receptacle 404 to the lateral flow test strip(s) 408 in the test strip holder 406 .
- the first receptacle 402 may include a lid 416 , such as to avoid spills of the bodily fluids from the first receptacle 402 .
- the transfer mechanism 410 may include a rotating piston 412 that may be rotated by interaction of the rotating piston 412 with a screw thread 430 .
- rotation of the rotating piston 412 may be initiated by a catalyst interacting with bodily fluids in a catalyst chamber 432 .
- the interaction of the catalyst with the bodily fluids may cause the combined catalyst and bodily fluids to expand, forcing the piston to move linearly (e.g., to the right in the view of FIG. 4 ) and to interact with the screw thread 430 , resulting in rotation of the rotating piston 412 .
- the rotation of the rotating piston 412 may occur automatically, without manual manipulation by a user.
- the catalyst in the catalyst chamber 432 may be any material or structure that expands upon interaction with the bodily fluids.
- the catalyst may include a foam precursor that expands upon mixing with water in the bodily fluids.
- the catalyst may include a physical structure, such as a sponge, that expands upon exposure to and absorption of the bodily fluids.
- the lateral flow test strip(s) 408 that are configured to detect one or more target substances may be positioned at least partially within the test strip holder 406 .
- a user may place bodily fluids to be tested within the first receptacle 402 and the lid 416 may be closed.
- a portion (e.g., in the amount of the second fluid volume) of the bodily fluids from the first receptacle 402 may drop into the second receptacle 404 and another portion of the bodily fluids may drop into the catalyst chamber 432 via gravity.
- the rotating piston 412 may be forced to move in a linear direction (e.g., to the right in the view of FIG. 4 ).
- the rotating piston 412 As the rotating piston 412 is forced in the linear direction, the rotating piston 412 may press against a surface of the screw thread 430 , causing the rotating piston 412 to rotate.
- the second fluid volume of the bodily fluids may then be transferred from the second receptacle 404 into the test strip holder 406 and ultimately onto the lateral flow test strip(s) 408 .
- the bodily fluids may be tested for the presence and/or quantity of the target substance(s), as described above with reference to FIGS. 1 A- 1 C .
- the lateral flow test strip(s) 408 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids.
- the device 400 including any excess bodily fluids that may remain within the first receptacle 402 , may be discarded, such as in an appropriate biohazard waste container.
- FIG. 5 is a cross-sectional side view of a device 500 for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure.
- the device 500 may be similar to the device 200 described above with reference to FIG. 2 .
- the device 500 may include a first receptacle 502 having a first fluid volume, a second receptacle 504 having a predetermined second fluid volume for application to one or more lateral flow test strips 508 , a test strip holder 506 for holding the lateral flow test strip(s) 508 , and a transfer mechanism 510 for transferring the second fluid volume of the bodily fluids from the second receptacle 504 to the lateral flow test strip(s) 508 in the test strip holder 306 .
- the first receptacle 502 may include a lid 516 , such as to avoid spills of the bodily fluids from the first receptacle 502 .
- the device 500 may be configured for simultaneous application of an appropriate volume of the bodily fluids to multiple lateral flow test strips 508 .
- the transfer mechanism 510 may include any of the transfer mechanisms 210 , 310 , 410 discussed above.
- the transfer mechanism 510 may optionally be diverted and applied to the multiple lateral flow test strips 508 with a flow diverter 534 .
- the multiple lateral flow test strips 508 may be respectively configured for simultaneous testing for multiple different respective target substances in the bodily fluids.
- the second fluid volume in the second receptacle 504 may be selected based on the quantity of lateral flow test strips 508 to be positioned in the test strip holder 506 .
- FIG. 6 is a flow chart illustrating a method 600 of lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure.
- the method 600 may be performed using any of the devices 100 , 200 , 300 , 400 , 500 discussed above with reference to FIGS. 1 A- 5 .
- bodily fluids may be received from a patient in a first receptacle having a first fluid volume. Operation 610 may be performed in a variety of ways. For example, bodily fluids including at least one of blood, urine, saliva, and/or effluent from a peritoneal dialysis treatment may be received in the first receptacle. The bodily fluids may be introduced into the first receptacle by pouring, injection, flowing through a conduit, etc. By way of example, the bodily fluids may be received from the patient in a clinic (e.g., doctor's office, testing facility, etc.), in a care facility, or in the patient's home.
- a clinic e.g., doctor's office, testing facility, etc.
- a portion of the bodily fluids may be passed from the first receptacle to a second receptacle.
- the second receptacle may have a predetermined second fluid volume that is selected to be applied to at least one lateral flow test strip.
- Operation 620 may be performed in a variety of ways.
- the portion of the bodily fluids may be flowed into the second receptacle by gravity or by forcing the portion of the bodily fluids into the second receptacle (e.g., by drawing in the portion of the bodily fluids with a syringe).
- the second fluid volume of the bodily fluids in the second receptacle may be applied to the at least one lateral flow test strip for lateral flow testing of the bodily fluids.
- Operation 630 may be performed in a variety of ways.
- the bodily fluids may be flowed into a test strip holder via gravity or by forcing the bodily fluids from the second receptacle into the test strip holder (e.g., by compressing a syringe holding the bodily fluids).
- a rotating piston including the second receptacle may be rotated from a first position for receiving the bodily fluids from the first receptacle to a second position for applying the bodily fluids from the second receptacle into the test strip holder and ultimately onto the lateral flow test strip(s).
- the bodily fluids from the second receptacle may be applied to a single lateral flow test strip or to multiple lateral flow test strips.
- FIG. 7 A is a perspective view of a device 700 for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure.
- FIG. 7 B is a cross-sectional side view of the device 700 of FIG. 7 A , taken at line A-A of FIG. 7 A .
- the device 700 may include one or more receptacles 702 for receiving bodily fluids from a patient. Each of the receptacles 702 may have a predetermined fluid volume that may be selected to be applied to at least one corresponding lateral flow test strip 708 in a test strip holder 706 .
- the device 700 may also include at least one overflow chamber 734 for receiving excess bodily fluids, such as bodily fluids that may overflow from the receptacle 702 .
- the overflow chamber 734 may be positioned under the test strip holder 706 .
- An absorbent material 736 (e.g., a sponge, fabric, etc.) may be positioned in the overflow chamber 734 and may be configured to absorb and hold the excess bodily fluid within the overflow chamber 734 , such as to reduce or eliminate spilling of the excess bodily fluid out of the overflow chamber 734 .
- One or more openings 738 in an upper surface 740 of the device 700 may provide fluid access to the overflow chamber 734 .
- the opening(s) 738 may be positioned at a lower elevation than an upper edge of the receptacles 702 .
- the upper surface 740 may slope downward from the upper edge of the receptacles 702 to the opening(s) 738 , as shown in FIG. 7 B .
- any excess bodily fluids may flow from the receptacles 702 downward to the opening(s) 738 and ultimately into the overflow chamber 734 .
- the upper surface 740 may be coated with a hydrophilic coating, such that the excess bodily fluids do not stick to the upper surface 740 and readily flow toward the overflow chamber 734 .
- a transparent covering 742 may be positioned over the test strip holder 706 to inhibit any excess bodily fluids from inadvertently reaching the lateral flow test strips 708 , other than through the receptacles 702 as intended.
- a lip 744 may extend upward from the upper surface 740 along a peripheral edge of the device 700 , such as to inhibit spilling any of the excess bodily fluids over the peripheral edge of the device 700 .
- test strip holder 706 may be sized to accommodate one, two, three, or more than four lateral flow test strips 708 .
- the device 700 may include one, two, three, four, or more than four corresponding receptacles 702 .
- the device 700 may include a single receptacle 702 for receiving bodily fluids from a patient, and the bodily fluids may be diverted for application to one or more lateral flow test strips 708 .
- a user may provide bodily fluids from a patient into the receptacle(s) 702 until the receptacle(s) 702 overflow to ensure that the predetermined fluid volume of the receptacle(s) 702 is full of the bodily fluids. Excess bodily fluids may flow through the opening(s) 738 and into the overflow chamber 734 .
- the bodily fluids from the receptacle(s) 702 may be applied to the lateral flow test strip(s) 708 and tested for the presence and/or quantity of the target substance(s), as described above with reference to FIGS. 1 A- 1 C .
- the lateral flow test strip(s) 708 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids.
- the device 700 including any excess bodily fluids that may remain within the overflow chamber 734 , may be discarded, such as in an appropriate biohazard waste container.
- FIG. 8 is a flow chart illustrating a method 800 of lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure.
- the method 800 may be performed using any of the devices 100 , 700 discussed above with reference to FIGS. 1 A- 1 C, 7 A, and 7 B .
- bodily fluids from a patient may be received in a receptacle.
- the receptacle may have a predetermined fluid volume that is selected to be applied to at least one lateral flow test strip.
- Operation 810 may be performed in a variety of ways.
- bodily fluids including at least one of blood, urine, saliva, and/or effluent from a peritoneal dialysis treatment may be received in the receptacle.
- the bodily fluids may be introduced into the receptacle by pouring, injection, flowing through a conduit, etc.
- the bodily fluids may be received from the patient in a clinic (e.g., doctor's office, testing facility, etc.), in a care facility, or in the patient's home.
- overflow bodily fluids in excess of the predetermined fluid volume from the receptacle may be received in an overflow chamber.
- Operation 820 may be performed in a variety of ways. For example, a user may stop applying bodily fluids to the receptacle when the user observes the bodily fluids overflowing from the receptacle. Any of the excess bodily fluids may flow into the overflow chamber through one or more openings in an upper surface adjacent to the receptacle. For example, the upper surface may be sloped downward from an upper edge of the receptacle toward the opening(s). In some embodiments, an absorbent material in the overflow chamber may capture and hold the excess bodily fluids.
- the predetermined fluid volume of the bodily fluids from the receptacle may be applied to at least one lateral flow test strip for lateral flow testing of the bodily fluids.
- Operation 830 may be performed in a variety of ways. For example, gravity may cause the bodily fluids within the receptacle to be applied to the lateral flow test strip(s). In the case of multiple lateral flow test strips, the bodily fluids may be directed to the multiple lateral flow test strips by a flow diverter.
- the present disclosure includes devices and methods for lateral flow testing of bodily fluids.
- Devices according to embodiments of the present disclosure may enable users to confidently apply a sufficient amount of bodily fluids to lateral flow test strips for effective testing, without causing problems that may be associated with the application of too much bodily fluids to the lateral flow test strips. Additionally, the devices may be simple to use and relatively inexpensive to manufacture.
- Example 1 A device for lateral flow testing of bodily fluids, which may include: a first receptacle for receiving bodily fluids from a patient, the first receptacle having a first fluid volume; a second receptacle positioned and configured to receive bodily fluids from the first receptacle, the second receptacle having a predetermined second fluid volume selected to be applied to at least one lateral flow test strip; and a test strip holder shaped to receive the at least one lateral flow test strip, wherein the test strip holder is positioned to receive the second fluid volume of bodily fluids from the second receptacle to test the bodily fluids via lateral flow along the at least one lateral flow test strip.
- Example 2 The device of Example 1, wherein the test strip holder is sized to receive multiple lateral flow test strips.
- Example 3 The device of Example 1 or Example 2, further including a transfer mechanism to move the fluid from the second receptacle to the test strip holder.
- Example 4 The device of Example 3, wherein the transfer mechanism includes a rotating piston configured to rotate the second receptacle from a first position to receive the second fluid volume of the bodily fluids from the first receptacle to a second position to pass the second fluid volume of the bodily fluids from the second receptacle to the test strip holder.
- the transfer mechanism includes a rotating piston configured to rotate the second receptacle from a first position to receive the second fluid volume of the bodily fluids from the first receptacle to a second position to pass the second fluid volume of the bodily fluids from the second receptacle to the test strip holder.
- Example 5 The device of Example 3 or Example 4, wherein the transfer mechanism includes a syringe configured to draw the second fluid volume of the bodily fluids from the first receptacle into the second receptacle and to pass the second fluid volume of the bodily fluids from the second receptacle to the test strip holder.
- the transfer mechanism includes a syringe configured to draw the second fluid volume of the bodily fluids from the first receptacle into the second receptacle and to pass the second fluid volume of the bodily fluids from the second receptacle to the test strip holder.
- Example 6 The device of any of Examples 3 through 5, wherein the transfer mechanism includes: a catalyst chamber in fluid communication with the first receptacle, the catalyst chamber configured to hold a catalyst that expands upon exposure to a sufficient volume of the bodily fluids; a rotating piston including the second receptacle; and a screw thread configured to rotate the rotating piston upon expansion of the catalyst into a position to pass the second fluid volume of the bodily fluids from the second receptacle into the test strip holder.
- the transfer mechanism includes: a catalyst chamber in fluid communication with the first receptacle, the catalyst chamber configured to hold a catalyst that expands upon exposure to a sufficient volume of the bodily fluids; a rotating piston including the second receptacle; and a screw thread configured to rotate the rotating piston upon expansion of the catalyst into a position to pass the second fluid volume of the bodily fluids from the second receptacle into the test strip holder.
- Example 7 The device of any of Examples 1 through 6, further including a lid for covering the first receptacle.
- Example 8 The device of any of Examples 1 through 7, wherein the test strip holder is removable and replaceable relative to the first receptacle and second receptacle.
- Example 9 A method of lateral flow testing of bodily fluids, which may include: receiving bodily fluids from a patient in a first receptacle having a first fluid volume; passing a portion of the bodily fluids from the first receptacle to a second receptacle having a predetermined second fluid volume that is selected to be applied to at least one lateral flow test strip; and applying the second fluid volume of the bodily fluids from the second receptacle to the at least one lateral flow test strip for lateral flow testing of the bodily fluids.
- Example 10 The method of Example 9, wherein receiving the bodily fluids from the patient includes receiving at least one of the following bodily fluids: blood; urine; saliva; or effluent from a peritoneal dialysis treatment.
- Example 11 The method of Example 9 or Example 10, wherein applying the second fluid volume of the bodily fluids from the second receptacle to the at least one lateral flow test strip includes rotating a piston including the second receptacle from a first position to a second position.
- Example 12 The method of any of Examples 9 through 11, wherein: passing the portion of the bodily fluids from the first receptacle to the second receptacle includes drawing the portion of the bodily fluids from the first receptacle into the second receptacle with a syringe; and applying the second fluid volume of the bodily fluids from the second receptacle to the at least one lateral flow test strip includes injecting the second fluid volume of the bodily fluids into fluid communication with the at least one lateral flow test strip with the syringe.
- Example 13 A device for lateral flow testing of bodily fluids, which may include: a receptacle for receiving bodily fluids from a patient, the receptacle having a predetermined fluid volume selected to be applied to at least one lateral flow test strip; an overflow chamber for receiving the bodily fluids in excess of the predetermined fluid volume; and a test strip holder shaped to receive the at least one lateral flow test strip, wherein the test strip holder is positioned to receive the predetermined fluid volume of bodily fluids from the receptacle to test the bodily fluids via lateral flow along the at least one lateral flow test strip.
- Example 14 The device of Example 13, wherein the overflow chamber is positioned under the test strip holder.
- Example 15 The device of Examples 13 or Example 14, wherein an upper surface of the device slopes downward from an edge of the receptacle to an opening of the overflow chamber.
- Example 16 The device of any of Examples 13 through 15, wherein the overflow chamber includes a plurality of openings to receive the bodily fluids that overflow from the receptacle.
- Example 17 The device of Example 16, wherein the plurality of openings are positioned along an end of the device adjacent to the receptacle and along lateral sides of the device.
- Example 18 The device of any of Examples 13 through 17, wherein the test strip holder is sized and configured to receive a plurality of lateral flow test strips.
- Example 19 The device of Example 18, wherein the receptacle comprises a plurality of receptacles corresponding to the plurality of lateral flow test strips, wherein each receptacle of the plurality of receptacles has a predetermined fluid volume selected to be applied to one corresponding lateral flow test strip of the plurality of lateral flow test strips.
- Example 20 The device of any of Examples 13 through 19, further comprising an absorbent material positioned in the overflow chamber and configured to absorb and hold the bodily fluids in excess of the predetermined fluid volume.
- Example 21 A method of lateral flow testing of bodily fluids, which may include: receiving bodily fluids from a patient in a receptacle having a predetermined fluid volume that is selected to be applied to at least one lateral flow test strip; receiving overflow bodily fluids in excess of the predetermined fluid volume from the receptacle in an overflow chamber; and applying the predetermined fluid volume of the bodily fluids from the receptacle to the at least one lateral flow test strip for lateral flow testing of the bodily fluids.
- Example 22 The method of Example 21, wherein receiving the overflow bodily fluids in excess of the predetermined fluid volume from the receptacle in the overflow chamber includes flowing the overflow bodily fluids downward from an upper edge of the receptacle to at least one opening of the overflow chamber.
- Example 23 The method of Example 21 or Example 22, wherein applying the predetermined fluid volume of the bodily fluids from the receptacle to the at least one lateral flow test strip includes flowing the overflow bodily fluids downward from an upper edge of the receptacle to at least one opening of the overflow chamber.
Abstract
The disclosed devices for lateral flow testing may include a receptacle for receiving bodily fluids from a patient that has a predetermined fluid volume for application to one or more lateral flow test strips. A test strip holder may be positioned to receive the predetermined fluid volume of the bodily fluids from the receptacle. Various other components, devices, and methods are also disclosed.
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 63/093,011, titled “DEVICES AND METHODS FOR LATERAL FLOW TESTS OF BODILY FLUIDS,” filed 16 Oct. 2020, the entire disclosure of which is incorporated herein by reference.
- Peritonitis is a major cause of morbidity and mortality in peritoneal dialysis (“PD”) patients globally. According to the International Society for Peritoneal Dialysis guidelines, peritonitis can be diagnosed when at least two of the following are present: (1) clinical features consistent with peritonitis, e.g., abdominal pain and/or cloudy dialysis effluent; (2) dialysis effluent with a white blood cell count greater than 100/μL or greater than 0.1×109/L (after a dwell time of at least two hours), with more than 50% of the white blood counts being polymorphonuclear; and (3) a positive peritoneal dialysis effluent culture.
- In practice, when a patient presents in the clinic with symptoms of peritonitis, it typically takes clinicians from a couple of hours to five days to get the results of a white blood cell count and peritoneal dialysis effluent cell culture. There is also about a 10% culture-negative rate even with infections.
- Once an infection diagnosis is made (without knowing the specific causative agent(s)), the nephrologist typically initiates empirical antibiotic therapy. Such therapy typically includes administering at least two different broad-spectrum antibiotics which collectively cover most of the gram-positive and gram-negative bacteria, along with an anti-fungal agent to prevent secondary fungal peritonitis until the causative agent(s) and drug susceptibility tests become available.
- Lateral flow tests (also commonly referred to as “lateral flow assays”) to diagnose peritonitis or other conditions have been developed. Generally speaking, a lateral flow test for peritonitis or other conditions are performed by placing a bodily fluid (also referred to as an “analyte”) that may contain a target substance functioning as a marker for the condition on an end of a prepared test strip, laying the test strip on a horizontal surface, and allowing the analyte to wick across the test strip via capillary action. As the fluid proceeds, if the target substance is present in the analyte, the target substance reacts with bioactive particles (also referred to as “conjugates”) and the combined target substance and bioactive particles proceed along the strip as the fluid proceeds. If a sufficient amount of the target substance is present, the combined target substance and bioactive particles congregate at a test line, and an indication (e.g., a color) of the presence of the target substance appears. If there is not enough (e.g., none) of the target substance in the analyte, then the indication does not appear at the test line or the indication is faint. Regardless of whether enough of the target substance is present in the analyte, a control indication may appear at a control line when the fluid reaches the control line, to indicate that the test was successfully completed.
- If insufficient analyte is applied to the strip, the fluid may not reach the control line, and no control indication will appear at the control line. Without a control indication appearing, another test may be required. If too much analyte is applied, the test may show a false positive. Additionally or alternatively, too much analyte may result in an oversaturated test strip and/or spills, which can present a hazard particularly when the analyte is a bodily fluid.
- The accompanying drawings illustrate a number of example embodiments and are a part of the specification. Together with the following description, these drawings demonstrate and explain various principles of the present disclosure.
-
FIGS. 1A-1C are perspective diagrams of a device for lateral flow testing of bodily fluids at various stages of operation, according to at least one embodiment of the present disclosure. -
FIG. 2 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure. -
FIG. 3 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure. -
FIG. 4 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure. -
FIG. 5 is a cross-sectional side view of a device for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure. -
FIG. 6 is a flow chart illustrating a method of lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure. -
FIG. 7A is a perspective view of a device for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure.FIG. 7B is a cross-sectional side view of the device ofFIG. 7A , taken at line A-A ofFIG. 7A . -
FIG. 8 is a flow chart illustrating a method of lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure. - Throughout the drawings, identical reference characters and descriptions indicate similar, but not necessarily identical, elements. While the example embodiments described herein are susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. However, the example embodiments described herein are not intended to be limited to the particular forms disclosed. Rather, the present disclosure covers all modifications, equivalents, and alternatives falling within the scope of the appended claims.
- The present disclosure is generally directed to devices and methods for lateral flow testing of bodily fluids, such as for peritonitis. In some examples, such devices may be configured to apply a predetermined, appropriate volume of a bodily fluid on a lateral flow test strip. For example, the device may include a first receptacle for receiving bodily fluids from a patient and a second receptacle configured to receive bodily fluids from the first receptacle. The first receptacle may include a first, relatively larger volume, and the second receptacle may include a second volume that is predetermined for application to one or more lateral flow test strips. In an additional example, the device may include a receptacle for receiving bodily fluids from a patient. The receptacle may have a predetermined fluid volume that is selected to be applied to at least one lateral flow test strip. An overflow chamber may be configured for receiving the bodily fluids in excess of the predetermined fluid volume (e.g., that may overflow from the receptacle).
- These and other example embodiments may enable the application of an appropriate amount of bodily fluid analyte on the lateral flow test strip(s), without additional complexity for the user. For example, the devices of the present disclosure may receive an excess of bodily fluids without the user needing to precisely measure the amount applied or without needing to time the exposure of the test strip to the fluid. The device may automatically apply the appropriate amount of the analyte to the lateral flow test strip(s).
- Features from any of the embodiments described herein may be used in combination with one another in accordance with the general principles described herein. These and other embodiments, features, and advantages will be more fully understood upon reading the following detailed description in conjunction with the accompanying drawings and claims.
- The following will provide, with reference to
FIGS. 1A-5, 7A, and 7B , detailed descriptions of devices for lateral flow testing of bodily fluids or other analytes, according to various embodiments of the present disclosure. With reference toFIGS. 6 and 8 , the following will provide detailed descriptions of methods for lateral flow testing of bodily fluids, according to additional embodiments of the present disclosure. -
FIGS. 1A-1C are perspective diagrams of adevice 100 for lateral flow testing of bodily fluids at various stages of operation, according to at least one embodiment of the present disclosure. Referring toFIG. 1A , thedevice 100 may include areceptacle 102 for ananalyte 104 from a patient (e.g., a peritoneal dialysis patient) for testing for the presence of a marker for a condition (e.g., peritonitis). A lateralflow test strip 106 may be positioned for receiving theanalyte 104 from thereceptacle 102 in awell portion 108. The lateralflow test strip 106 may also include aconjugate pad 110, amembrane 112, atest line 114, acontrol line 116, and anabsorbent pad 118. - The
receptacle 102 may have a size and shape to hold a predetermined volume of theanalyte 104 for application of an appropriate amount of theanalyte 104 to the lateralflow test strip 106. Anyanalyte 104 in excess of the predetermined volume may be kept away (e.g., diverted away, held in another receptacle, etc.) from the lateralflow test strip 106. Some suitable examples for keepingexcess analyte 104 away from the lateralflow test strip 106 are described below with reference toFIGS. 2-5, 7A, and 7B . - The
analyte 104 may be a bodily fluid or any other fluid to be tested for the detection and/or quantification of atarget substance 120 that may be in theanalyte 104. For example, theanalyte 104 may be or include a sample of blood, urine, saliva, effluent from a peritoneal dialysis treatment, etc., from a patient. Thetarget substance 120 may be a marker for a condition, such as peritonitis, a pathogen, pregnancy, etc. For example, thetarget substance 120 may be or include an antibody, a protein, a hormone, an antigen, bacteria, a fungus, etc. - The
well portion 108 may be an adsorbent pad configured to receive theanalyte 104 and to prepare the analyte 104 (e.g., via a surfactant, buffer salt, etc.) for analysis by the lateralflow test strip 106. - The
conjugate pad 110 may contain conjugates 122 (e.g., bioactive particles, such as antibodies) that may be reactive specifically to thetarget substance 120. For example, as shown inFIG. 1B , when theanalyte 104 is conveyed along the lateralflow test strip 106, particles of thetarget substance 120 may be chemically bound to theconjugates 122. Theconjugates 122 may include detectable particles, such as gold or latex microspheres for visual detection. Other detectable particles may also be used, such as fluorescent particles and/or magnetic particles. Theconjugates 122 may be maintained in a functionally stable state prior to use, such as by coating theconjugates 122 in a water-soluble material, such as sucrose. When theanalyte 104 reaches theconjugates 122, the sucrose or other coating may dissolve into water of theanalyte 104, exposing and chemically activating theconjugates 122 for reaction (e.g., for chemically binding) with thetarget substance 120. - As illustrated in
FIG. 1B , themembrane 112 may be configured to further convey theanalyte 104 along the lateralflow test strip 106, such as by capillary action. The membrane may include, for example, a cellulose material or other porous material configured to convey theanalyte 104 along the lateralflow test strip 106. - The
test line 114 may be a region of themembrane 112 with immobilizedanti-analyte particles 124, which may be selected to react with particles of thetarget substance 120 that have been bound to theconjugates 122. As illustrated inFIG. 1C , the boundtarget substance 120 andconjugates 122 may react with theanti-analyte particles 124 and may congregate along thetest line 114. When thetarget substance 120 is present in theanalyte 104 in sufficient quantities, a detectable signal may be produced along thetest line 114. For example, a visible color (e.g., from colored particles of the conjugates 122), fluorescent line, magnetic line, etc., may appear along thetest line 114 to indicate that a sufficient quantity of thetarget substance 120 is present in theanalyte 104. If there is insufficient (e.g., no)target substance 120 in theanalyte 104, then theconjugates 122 may be conveyed past thetest line 114, since theanti-analyte particles 124 may be non-reactive with theconjugates 122 lacking thetarget substance 120. - The
control line 116 may be a region of themembrane 112 with immobilizedanti-conjugate particles 126, which may be selected to react with theconjugates 122. As illustrated inFIG. 1C , theconjugates 122 may react with theanti-conjugate particles 126 and may congregate along thecontrol line 116. This may provide an indication that the lateralflow test strip 106 has successfully conveyed theanalyte 104 across thetest line 114, regardless of whether there is enough of thetarget substance 120 in theanalyte 104 to form a positive indication on thetest line 114. Thus, after thecontrol line 116 indicates that the test has been completed, thetest line 114 may be analyzed for a positive or negative result. - Any
additional analyte 104 may be conveyed past thecontrol line 116 to theabsorbent pad 118. For example, theabsorbent pad 118 may be a sponge or other porous material configured to soak up and containadditional analyte 104. - By way of example and not limitation, various lateral flow testing concepts will next be described. These lateral flow testing concepts may be combined with the
device 100 and related concepts as described above. Other concepts known to those skilled in the art of lateral flow testing may also be used. - The antigen indicative of an inflammatory response in the peritoneum may be neutrophil gelatinase-associated lipocalin, interleukin 1, interleukin 6, interleukin 8, tumor necrosis factor α, procalcitonin, and/or C-reactive protein. Lipoteichoic acid is an antigen indicative of the presence of gram-positive bacteria. Lipopolysaccharide is an antigen indicative of the presence of gram-negative bacteria. β-glucan is an antigen indicative of the presence of a fungus. For diagnosing peritonitis, the pathogen may be at least one bacterium and/or fungus.
- In some embodiments, the
conjugates 122 may include a binding molecule that specifically binds an antigen indicative of the presence of a specific pathogen species. For use with a peritoneal dialysis effluent, the specific pathogen may be Staphylococcus aureus, Pseudomonas sp., Staphylococcus epidermidis, Staphylococcus haemolyticus, Candida sp., Escherichia coli, vancomycin-resistant enterococci, or combinations thereof. - In some examples, the lateral
flow test strip 106 may include a buffer that specifically elutes antigen(s), such as in thewell portion 108 of the lateralflow test strip 106. The buffer composition may be chosen to selectively stabilize the antigen and/or antigen-antibody complex, maintain pH, and/or maintain or disrupt structure or binding of the antigen-antibody complex. - In certain embodiments, the
device 100 may be used to diagnose peritonitis in a patient by detecting, in a peritoneal dialysis effluent analyte, an antigen indicative of an inflammatory response having been launched in the peritoneum, detecting an antigen indicative of the presence of a gram-positive bacteria, detecting an antigen indicative of the presence of a gram-negative bacteria, and/or detecting an antigen indicative of the presence of a fungus. - In some embodiment, the
analyte 104 may include a peritoneal dialysis effluent that is taken directly from the patient and applied to thedevice 100, or the peritoneal dialysis effluent may be concentrated, filtered, and/or enriched prior to application to thedevice 100. In certain embodiments, enrichment may be by, for example, placing the peritoneal dialysis effluent sample into a conical tube, followed by centrifugation of the sample, and treatment with, e.g., a lysis buffer, extraction buffer, and/or neutralization buffer. Enrichment of a peritoneal dialysis effluent sample for antigens may also be by use of an ultrafiltration (“UF”) membrane (e.g., molecular weight cutoff 29,000). In another embodiment, a syringe may be used to pass/push the peritoneal dialysis effluent sample through a UF membrane instead of using a centrifuge. - Such diagnostic methods can be used to treat peritonitis in the patient by first diagnosing the patient as having peritonitis and then administering an appropriate antibiotic to the subject to treat the peritonitis in view of the diagnosis.
- The concepts discussed above with reference to
FIGS. 1A-1C may be employed in conjunction with any of the examples discussed below with reference toFIGS. 2-8 . -
FIG. 2 is a cross-sectional side view of adevice 200 for lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure. Thedevice 200 may include afirst receptacle 202 for receiving bodily fluids from a patient and asecond receptacle 204 positioned for receiving a portion of the bodily fluids from thefirst receptacle 202. Atest strip holder 206 may be positioned under thesecond receptacle 204 to receive the bodily fluids from thesecond receptacle 204. - The
first receptacle 202 may have a first fluid volume, which may be larger than is needed to perform a successful lateral flow test. Thesecond receptacle 204 may have a predetermined second fluid volume that is selected to be applied to at least one lateralflow test strip 208 inserted in thetest strip holder 206. For example, the second fluid volume may be selected to apply a sufficient amount of the bodily fluids to the at least one lateralflow test strip 208 for a complete and successful test, but not so much that the lateral flow test strip(s) 208 become oversaturated. - In some examples, relational terms, such as “first,” “second,” “upper,” “below,” etc., may be used for clarity and convenience in understanding the disclosure and accompanying drawings and may not necessarily connote or depend on any specific preference, orientation, or order, except where the context clearly indicates otherwise.
- Referring again to
FIG. 2 , thedevice 200 may also include atransfer mechanism 210 to move the bodily fluid from thesecond receptacle 204 to thetest strip holder 206 and ultimately to the at least one lateralflow test strip 208. In the example shown inFIG. 2 , thetransfer mechanism 210 may include arotating piston 212 that may be configured to rotate thesecond receptacle 204 from a first position (shown inFIG. 2 in solid lines) for receiving the bodily fluid from thefirst receptacle 202 to a second position (shown inFIG. 2 in dashed lines) for transferring (e.g., via gravity) the bodily fluid from thesecond receptacle 204 to thetest strip holder 206. Therotating piston 212 may be biased (e.g., spring-biased) to the first position, such as to avoid inadvertent spilling of bodily fluids through thesecond receptacle 204 andtest strip holder 206. In some embodiments, therotating piston 212 may include aknob 214 to enable a user to grasp and rotate therotating piston 212 into the second position after the bodily fluids are positioned in thefirst receptacle 202 and allowed to flow into thesecond receptacle 204. - In some embodiments, the
first receptacle 204 may include alid 216 for covering thefirst receptacle 204. Thelid 216 may be configured to provide a fluid-tight seal (e.g., via an O-ring and a clasp 218), which may reduce or eliminate a chance of spilling the bodily fluids within thefirst receptacle 204 when thelid 216 is closed. - In some examples, the
test strip holder 206 may be removable and replaceable relative to thefirst receptacle 202 andsecond receptacle 204. For example, thetest strip holder 206 may be used with thefirst receptacle 202 andsecond receptacle 204 to test bodily fluids positioned within thefirst receptacle 202, and then thetest strip holder 206 with its lateral flow test strip(s) 208 may be decoupled from thefirst receptacle 202 andsecond receptacle 204. A replacementtest strip holder 206 with one or more unused lateral flow test strip(s) 208 may be coupled to thefirst receptacle 202 andsecond receptacle 204 to run another test on the bodily fluids within thefirst receptacle 202. Thus, multiple tests may be sequentially performed on the bodily fluids within thefirst receptacle 202, without the need for obtaining a new sample from the patient for each test. - In operation, a user may place bodily fluids to be tested within the
first receptacle 202 and thelid 216 may be closed. The lateral flow test strip(s) 208 that are configured to detect one or more target substances may be positioned at least partially within thetest strip holder 206. A portion of the bodily fluids may be allowed flow into thesecond receptacle 204. The user may rotate theknob 214 to transfer the predetermined second volume of the bodily fluids from thesecond receptacle 204 to the lateral flow test strip(s) 208. The bodily fluids may be conveyed along the lateral flow test strip(s) 208 and tested for the presence and/or quantity of the target substance(s), as described above with reference toFIGS. 1A-1C . After a given time (depending on the lateral flow test strip(s) 208 used), the lateral flow test strip(s) 208 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids. After the results of the test are obtained, thedevice 200, including any excess bodily fluids that may remain within thefirst receptacle 202, may be discarded, such as in an appropriate biohazard waste container. -
FIG. 3 is a cross-sectional side view of adevice 300 for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure. Thedevice 300 may be similar to thedevice 200 described above with reference toFIG. 2 . For example, thedevice 300 may include afirst receptacle 302 having a first fluid volume, asecond receptacle 304 having a predetermined second fluid volume for application to one or more lateralflow test strips 308, atest strip holder 306 for holding the lateral flow test strip(s) 308, and atransfer mechanism 310 for transferring the second fluid volume of the bodily fluids from thesecond receptacle 304 to the lateral flow test strip(s) 308 in thetest strip holder 306. Thefirst receptacle 302 may include alid 316, such as to avoid spills of the bodily fluids from thefirst receptacle 302. - As shown in the example illustrated in
FIG. 3 , thetransfer mechanism 310 may include asyringe 320 positioned and configured to withdraw the second fluid volume of the bodily fluids from thefirst receptacle 302. Thesecond receptacle 304 may be defined by an internal volume of thesyringe 320 when a plunger of thesyringe 320 is fully withdrawn. A first one-way channel 322 (e.g., a first check valve) may be positioned between thefirst receptacle 302 and thesecond receptacle 304. The first one-way channel 322 may be configured to let fluid flow from thefirst receptacle 302 into thesecond receptacle 304, but may inhibit (e.g., prevent) the flow of fluid from thesecond receptacle 304 back into thefirst receptacle 304. A second one-way channel 324 (e.g., a second check valve) may be positioned between thesecond receptacle 304 and thetest strip holder 306. The second one-way channel 324 may be configured to let fluid flow from thesecond receptacle 304 into thetest strip holder 306, but may inhibit (e.g., prevent) the flow of fluid from thetest strip holder 306 into thesecond receptacle 304. Thesyringe 320 may include aknob 326 for a user to grasp thesyringe 320 to operate thedevice 300. - In additional embodiments, the
syringe 320 may be mounted to apivot 328. Thesecond receptacle 304 may be in fluid communication with thefirst receptacle 302 when thesyringe 320 and pivot 328 are in a first position (shown inFIG. 3 ). Thesyringe 320 may be rotated about the pivot 328 (e.g., in a counterclockwise direction from the perspective ofFIG. 3 ) to orient thesyringe 320 such that thesecond receptacle 304 is in fluid communication with thetest strip holder 306. - In operation, a user may place bodily fluids to be tested within the
first receptacle 302 and thelid 316 may be closed. The lateral flow test strip(s) 308 that are configured to detect one or more target substances may be positioned at least partially within thetest strip holder 306. The user may grasp and pull theknob 326 to draw the second fluid volume of the bodily fluids with thesyringe 320 from thefirst receptacle 302 through the first one-way channel 322 and into thesecond receptacle 304. In embodiments in which thesyringe 320 is mounted to thepivot 328, the user may rotate thesyringe 320 using the pivot from the first position to the second position. Whether or not thepivot 328 is present, the user may then push on theknob 326 to force the second fluid volume of the bodily fluids from thesecond receptacle 304 into thetest strip holder 306 and ultimately onto the lateral flow test strip(s) 308. The bodily fluids may be tested for the presence and/or quantity of the target substance(s), as described above with reference toFIGS. 1A-1C . After a given time (depending on the lateral flow test strip(s) 308 used), the lateral flow test strip(s) 308 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids. After the results of the test are obtained, thedevice 300, including any excess bodily fluids that may remain within thefirst receptacle 302, may be discarded, such as in an appropriate biohazard waste container. -
FIG. 4 is a cross-sectional side view of adevice 400 for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure. Thedevice 400 may be similar to thedevice 200 described above with reference toFIG. 2 . For example, thedevice 400 may include afirst receptacle 402 having a first fluid volume, asecond receptacle 404 having a predetermined second fluid volume for application to one or more lateralflow test strips 408, atest strip holder 406 for holding the lateral flow test strip(s) 408, and atransfer mechanism 410 for transferring the second fluid volume of the bodily fluids from thesecond receptacle 404 to the lateral flow test strip(s) 408 in thetest strip holder 406. Thefirst receptacle 402 may include alid 416, such as to avoid spills of the bodily fluids from thefirst receptacle 402. - As shown in the example illustrated in
FIG. 4 , thetransfer mechanism 410 may include arotating piston 412 that may be rotated by interaction of therotating piston 412 with ascrew thread 430. In this embodiment, rotation of therotating piston 412 may be initiated by a catalyst interacting with bodily fluids in acatalyst chamber 432. The interaction of the catalyst with the bodily fluids may cause the combined catalyst and bodily fluids to expand, forcing the piston to move linearly (e.g., to the right in the view ofFIG. 4 ) and to interact with thescrew thread 430, resulting in rotation of therotating piston 412. In this example, the rotation of therotating piston 412 may occur automatically, without manual manipulation by a user. - The catalyst in the
catalyst chamber 432 may be any material or structure that expands upon interaction with the bodily fluids. For example, the catalyst may include a foam precursor that expands upon mixing with water in the bodily fluids. In additional examples, the catalyst may include a physical structure, such as a sponge, that expands upon exposure to and absorption of the bodily fluids. - In operation, the lateral flow test strip(s) 408 that are configured to detect one or more target substances may be positioned at least partially within the
test strip holder 406. A user may place bodily fluids to be tested within thefirst receptacle 402 and thelid 416 may be closed. A portion (e.g., in the amount of the second fluid volume) of the bodily fluids from thefirst receptacle 402 may drop into thesecond receptacle 404 and another portion of the bodily fluids may drop into thecatalyst chamber 432 via gravity. As the catalyst reacts with the bodily fluids in thecatalyst chamber 432 and expands, therotating piston 412 may be forced to move in a linear direction (e.g., to the right in the view ofFIG. 4 ). As therotating piston 412 is forced in the linear direction, therotating piston 412 may press against a surface of thescrew thread 430, causing therotating piston 412 to rotate. The second fluid volume of the bodily fluids may then be transferred from thesecond receptacle 404 into thetest strip holder 406 and ultimately onto the lateral flow test strip(s) 408. The bodily fluids may be tested for the presence and/or quantity of the target substance(s), as described above with reference toFIGS. 1A-1C . After a given time (depending on the lateral flow test strip(s) 408 used), the lateral flow test strip(s) 408 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids. After the results of the test are obtained, thedevice 400, including any excess bodily fluids that may remain within thefirst receptacle 402, may be discarded, such as in an appropriate biohazard waste container. -
FIG. 5 is a cross-sectional side view of adevice 500 for lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure. Thedevice 500 may be similar to thedevice 200 described above with reference toFIG. 2 . For example, thedevice 500 may include afirst receptacle 502 having a first fluid volume, asecond receptacle 504 having a predetermined second fluid volume for application to one or more lateralflow test strips 508, atest strip holder 506 for holding the lateral flow test strip(s) 508, and atransfer mechanism 510 for transferring the second fluid volume of the bodily fluids from thesecond receptacle 504 to the lateral flow test strip(s) 508 in thetest strip holder 306. Thefirst receptacle 502 may include alid 516, such as to avoid spills of the bodily fluids from thefirst receptacle 502. - As shown in the example illustrated in
FIG. 5 , thedevice 500 may be configured for simultaneous application of an appropriate volume of the bodily fluids to multiple lateral flow test strips 508. By way of example and not limitation, thetransfer mechanism 510 may include any of thetransfer mechanisms transfer mechanism 510 is used to transfer the bodily fluids from thesecond receptacle 504 to thetest strip holder 506, the bodily fluids may optionally be diverted and applied to the multiple lateralflow test strips 508 with aflow diverter 534. In some embodiments, the multiple lateralflow test strips 508 may be respectively configured for simultaneous testing for multiple different respective target substances in the bodily fluids. In this example, the second fluid volume in thesecond receptacle 504 may be selected based on the quantity of lateralflow test strips 508 to be positioned in thetest strip holder 506. -
FIG. 6 is a flow chart illustrating amethod 600 of lateral flow testing of bodily fluids, according to at least one embodiment of the present disclosure. By way of example and not limitation, themethod 600 may be performed using any of thedevices FIGS. 1A-5 . - At
operation 610, bodily fluids may be received from a patient in a first receptacle having a first fluid volume.Operation 610 may be performed in a variety of ways. For example, bodily fluids including at least one of blood, urine, saliva, and/or effluent from a peritoneal dialysis treatment may be received in the first receptacle. The bodily fluids may be introduced into the first receptacle by pouring, injection, flowing through a conduit, etc. By way of example, the bodily fluids may be received from the patient in a clinic (e.g., doctor's office, testing facility, etc.), in a care facility, or in the patient's home. - At
operation 620, a portion of the bodily fluids may be passed from the first receptacle to a second receptacle. The second receptacle may have a predetermined second fluid volume that is selected to be applied to at least one lateral flow test strip.Operation 620 may be performed in a variety of ways. For example, the portion of the bodily fluids may be flowed into the second receptacle by gravity or by forcing the portion of the bodily fluids into the second receptacle (e.g., by drawing in the portion of the bodily fluids with a syringe). - At
operation 630, the second fluid volume of the bodily fluids in the second receptacle may be applied to the at least one lateral flow test strip for lateral flow testing of the bodily fluids.Operation 630 may be performed in a variety of ways. For example, the bodily fluids may be flowed into a test strip holder via gravity or by forcing the bodily fluids from the second receptacle into the test strip holder (e.g., by compressing a syringe holding the bodily fluids). In some examples, a rotating piston including the second receptacle may be rotated from a first position for receiving the bodily fluids from the first receptacle to a second position for applying the bodily fluids from the second receptacle into the test strip holder and ultimately onto the lateral flow test strip(s). The bodily fluids from the second receptacle may be applied to a single lateral flow test strip or to multiple lateral flow test strips. -
FIG. 7A is a perspective view of adevice 700 for lateral flow testing of bodily fluids, according to at least one additional embodiment of the present disclosure.FIG. 7B is a cross-sectional side view of thedevice 700 ofFIG. 7A , taken at line A-A ofFIG. 7A . - The
device 700 may include one ormore receptacles 702 for receiving bodily fluids from a patient. Each of thereceptacles 702 may have a predetermined fluid volume that may be selected to be applied to at least one corresponding lateralflow test strip 708 in atest strip holder 706. Thedevice 700 may also include at least oneoverflow chamber 734 for receiving excess bodily fluids, such as bodily fluids that may overflow from thereceptacle 702. For example, as illustrated inFIG. 7B , theoverflow chamber 734 may be positioned under thetest strip holder 706. An absorbent material 736 (e.g., a sponge, fabric, etc.) may be positioned in theoverflow chamber 734 and may be configured to absorb and hold the excess bodily fluid within theoverflow chamber 734, such as to reduce or eliminate spilling of the excess bodily fluid out of theoverflow chamber 734. - One or
more openings 738 in anupper surface 740 of thedevice 700 may provide fluid access to theoverflow chamber 734. In some examples, the opening(s) 738 may be positioned at a lower elevation than an upper edge of thereceptacles 702. Theupper surface 740 may slope downward from the upper edge of thereceptacles 702 to the opening(s) 738, as shown inFIG. 7B . Thus, any excess bodily fluids may flow from thereceptacles 702 downward to the opening(s) 738 and ultimately into theoverflow chamber 734. In some examples, theupper surface 740 may be coated with a hydrophilic coating, such that the excess bodily fluids do not stick to theupper surface 740 and readily flow toward theoverflow chamber 734. - In some embodiments, a
transparent covering 742 may be positioned over thetest strip holder 706 to inhibit any excess bodily fluids from inadvertently reaching the lateralflow test strips 708, other than through thereceptacles 702 as intended. Alip 744 may extend upward from theupper surface 740 along a peripheral edge of thedevice 700, such as to inhibit spilling any of the excess bodily fluids over the peripheral edge of thedevice 700. - Although four lateral
flow test strips 708 are shown in thedevice 700 ofFIG. 7A , the present disclosure is not so limited. In additional embodiments, thetest strip holder 706 may be sized to accommodate one, two, three, or more than four lateral flow test strips 708. Thedevice 700 may include one, two, three, four, or more than fourcorresponding receptacles 702. In additional embodiments, thedevice 700 may include asingle receptacle 702 for receiving bodily fluids from a patient, and the bodily fluids may be diverted for application to one or more lateral flow test strips 708. - In operation, a user may provide bodily fluids from a patient into the receptacle(s) 702 until the receptacle(s) 702 overflow to ensure that the predetermined fluid volume of the receptacle(s) 702 is full of the bodily fluids. Excess bodily fluids may flow through the opening(s) 738 and into the
overflow chamber 734. The bodily fluids from the receptacle(s) 702 may be applied to the lateral flow test strip(s) 708 and tested for the presence and/or quantity of the target substance(s), as described above with reference toFIGS. 1A-1C . After a given time (depending on the lateral flow test strip(s) 708 used), the lateral flow test strip(s) 708 may provide an indication of the presence and/or quantity of the target substance(s) in the bodily fluids. After the results of the test are obtained, thedevice 700, including any excess bodily fluids that may remain within theoverflow chamber 734, may be discarded, such as in an appropriate biohazard waste container. -
FIG. 8 is a flow chart illustrating amethod 800 of lateral flow testing of bodily fluids, according to at least one other embodiment of the present disclosure. By way of example and not limitation, themethod 800 may be performed using any of thedevices FIGS. 1A-1C, 7A, and 7B . - At
operation 810, bodily fluids from a patient may be received in a receptacle. The receptacle may have a predetermined fluid volume that is selected to be applied to at least one lateral flow test strip.Operation 810 may be performed in a variety of ways. For example, bodily fluids including at least one of blood, urine, saliva, and/or effluent from a peritoneal dialysis treatment may be received in the receptacle. The bodily fluids may be introduced into the receptacle by pouring, injection, flowing through a conduit, etc. By way of example, the bodily fluids may be received from the patient in a clinic (e.g., doctor's office, testing facility, etc.), in a care facility, or in the patient's home. - At
operation 820, overflow bodily fluids in excess of the predetermined fluid volume from the receptacle may be received in an overflow chamber.Operation 820 may be performed in a variety of ways. For example, a user may stop applying bodily fluids to the receptacle when the user observes the bodily fluids overflowing from the receptacle. Any of the excess bodily fluids may flow into the overflow chamber through one or more openings in an upper surface adjacent to the receptacle. For example, the upper surface may be sloped downward from an upper edge of the receptacle toward the opening(s). In some embodiments, an absorbent material in the overflow chamber may capture and hold the excess bodily fluids. - At
operation 830, the predetermined fluid volume of the bodily fluids from the receptacle may be applied to at least one lateral flow test strip for lateral flow testing of the bodily fluids.Operation 830 may be performed in a variety of ways. For example, gravity may cause the bodily fluids within the receptacle to be applied to the lateral flow test strip(s). In the case of multiple lateral flow test strips, the bodily fluids may be directed to the multiple lateral flow test strips by a flow diverter. - Accordingly, the present disclosure includes devices and methods for lateral flow testing of bodily fluids. Devices according to embodiments of the present disclosure may enable users to confidently apply a sufficient amount of bodily fluids to lateral flow test strips for effective testing, without causing problems that may be associated with the application of too much bodily fluids to the lateral flow test strips. Additionally, the devices may be simple to use and relatively inexpensive to manufacture.
- The following example embodiments are also included in the present disclosure.
- Example 1: A device for lateral flow testing of bodily fluids, which may include: a first receptacle for receiving bodily fluids from a patient, the first receptacle having a first fluid volume; a second receptacle positioned and configured to receive bodily fluids from the first receptacle, the second receptacle having a predetermined second fluid volume selected to be applied to at least one lateral flow test strip; and a test strip holder shaped to receive the at least one lateral flow test strip, wherein the test strip holder is positioned to receive the second fluid volume of bodily fluids from the second receptacle to test the bodily fluids via lateral flow along the at least one lateral flow test strip.
- Example 2: The device of Example 1, wherein the test strip holder is sized to receive multiple lateral flow test strips.
- Example 3: The device of Example 1 or Example 2, further including a transfer mechanism to move the fluid from the second receptacle to the test strip holder.
- Example 4: The device of Example 3, wherein the transfer mechanism includes a rotating piston configured to rotate the second receptacle from a first position to receive the second fluid volume of the bodily fluids from the first receptacle to a second position to pass the second fluid volume of the bodily fluids from the second receptacle to the test strip holder.
- Example 5: The device of Example 3 or Example 4, wherein the transfer mechanism includes a syringe configured to draw the second fluid volume of the bodily fluids from the first receptacle into the second receptacle and to pass the second fluid volume of the bodily fluids from the second receptacle to the test strip holder.
- Example 6: The device of any of Examples 3 through 5, wherein the transfer mechanism includes: a catalyst chamber in fluid communication with the first receptacle, the catalyst chamber configured to hold a catalyst that expands upon exposure to a sufficient volume of the bodily fluids; a rotating piston including the second receptacle; and a screw thread configured to rotate the rotating piston upon expansion of the catalyst into a position to pass the second fluid volume of the bodily fluids from the second receptacle into the test strip holder.
- Example 7: The device of any of Examples 1 through 6, further including a lid for covering the first receptacle.
- Example 8: The device of any of Examples 1 through 7, wherein the test strip holder is removable and replaceable relative to the first receptacle and second receptacle.
- Example 9: A method of lateral flow testing of bodily fluids, which may include: receiving bodily fluids from a patient in a first receptacle having a first fluid volume; passing a portion of the bodily fluids from the first receptacle to a second receptacle having a predetermined second fluid volume that is selected to be applied to at least one lateral flow test strip; and applying the second fluid volume of the bodily fluids from the second receptacle to the at least one lateral flow test strip for lateral flow testing of the bodily fluids.
- Example 10: The method of Example 9, wherein receiving the bodily fluids from the patient includes receiving at least one of the following bodily fluids: blood; urine; saliva; or effluent from a peritoneal dialysis treatment.
- Example 11: The method of Example 9 or Example 10, wherein applying the second fluid volume of the bodily fluids from the second receptacle to the at least one lateral flow test strip includes rotating a piston including the second receptacle from a first position to a second position.
- Example 12: The method of any of Examples 9 through 11, wherein: passing the portion of the bodily fluids from the first receptacle to the second receptacle includes drawing the portion of the bodily fluids from the first receptacle into the second receptacle with a syringe; and applying the second fluid volume of the bodily fluids from the second receptacle to the at least one lateral flow test strip includes injecting the second fluid volume of the bodily fluids into fluid communication with the at least one lateral flow test strip with the syringe.
- Example 13: A device for lateral flow testing of bodily fluids, which may include: a receptacle for receiving bodily fluids from a patient, the receptacle having a predetermined fluid volume selected to be applied to at least one lateral flow test strip; an overflow chamber for receiving the bodily fluids in excess of the predetermined fluid volume; and a test strip holder shaped to receive the at least one lateral flow test strip, wherein the test strip holder is positioned to receive the predetermined fluid volume of bodily fluids from the receptacle to test the bodily fluids via lateral flow along the at least one lateral flow test strip.
- Example 14: The device of Example 13, wherein the overflow chamber is positioned under the test strip holder.
- Example 15: The device of Examples 13 or Example 14, wherein an upper surface of the device slopes downward from an edge of the receptacle to an opening of the overflow chamber.
- Example 16: The device of any of Examples 13 through 15, wherein the overflow chamber includes a plurality of openings to receive the bodily fluids that overflow from the receptacle.
- Example 17: The device of Example 16, wherein the plurality of openings are positioned along an end of the device adjacent to the receptacle and along lateral sides of the device.
- Example 18: The device of any of Examples 13 through 17, wherein the test strip holder is sized and configured to receive a plurality of lateral flow test strips.
- Example 19: The device of Example 18, wherein the receptacle comprises a plurality of receptacles corresponding to the plurality of lateral flow test strips, wherein each receptacle of the plurality of receptacles has a predetermined fluid volume selected to be applied to one corresponding lateral flow test strip of the plurality of lateral flow test strips.
- Example 20: The device of any of Examples 13 through 19, further comprising an absorbent material positioned in the overflow chamber and configured to absorb and hold the bodily fluids in excess of the predetermined fluid volume.
- Example 21: A method of lateral flow testing of bodily fluids, which may include: receiving bodily fluids from a patient in a receptacle having a predetermined fluid volume that is selected to be applied to at least one lateral flow test strip; receiving overflow bodily fluids in excess of the predetermined fluid volume from the receptacle in an overflow chamber; and applying the predetermined fluid volume of the bodily fluids from the receptacle to the at least one lateral flow test strip for lateral flow testing of the bodily fluids.
- Example 22: The method of Example 21, wherein receiving the overflow bodily fluids in excess of the predetermined fluid volume from the receptacle in the overflow chamber includes flowing the overflow bodily fluids downward from an upper edge of the receptacle to at least one opening of the overflow chamber.
- Example 23: The method of Example 21 or Example 22, wherein applying the predetermined fluid volume of the bodily fluids from the receptacle to the at least one lateral flow test strip includes flowing the overflow bodily fluids downward from an upper edge of the receptacle to at least one opening of the overflow chamber.
- The preceding description has been provided to enable others skilled in the art to best utilize various aspects of the example embodiments disclosed herein. This example description is not intended to be exhaustive or to be limited to any precise form disclosed. Many modifications and variations are possible without departing from the spirit and scope of the present disclosure. The embodiments disclosed herein should be considered in all respects illustrative and not restrictive. Reference should be made to the appended claims and their equivalents in determining the scope of the present disclosure.
- Unless otherwise noted, the terms “connected to” and “coupled to” (and their derivatives), as used in the specification and claims, are to be construed as permitting both direct and indirect (i.e., via other elements or components) connection. In addition, the terms “a” or “an,” as used in the specification and claims, are to be construed as meaning “at least one of” Finally, for ease of use, the terms “including” and “having” (and their derivatives), as used in the specification and claims, are interchangeable with and have the same meaning as the word “comprising.”
Claims (15)
1.-20. (canceled)
21. A device for lateral flow testing of bodily fluids, the device comprising:
a receptacle for receiving bodily fluids from a patient, the receptacle having a predetermined fluid volume selected to be applied to at least one lateral flow test strip;
an overflow chamber for receiving the bodily fluids in excess of the predetermined fluid volume; and
a test strip holder shaped to receive the at least one lateral flow test strip, wherein the test strip holder is positioned to receive the predetermined fluid volume of bodily fluids from the receptacle to test the bodily fluids via lateral flow along the at least one lateral flow test strip.
22. The device of claim 21 , wherein the overflow chamber is positioned under the test strip holder.
23. The device of claim 21 , wherein the overflow chamber comprises an opening in an upper surface of the device.
24. The device of claim 23 , wherein the opening is positioned at a lower elevation relative to an upper edge of the receptacle.
25. The device of claim 24 , wherein the upper surface of the device slopes downward from the upper edge of the receptacle to the opening of the overflow chamber.
26. The device of claim 21 , wherein the overflow chamber comprises a plurality of openings in an upper surface of the device, to receive the bodily fluids that overflow from the receptacle.
27. The device of claim 26 , wherein the plurality of openings are positioned along an end of the device adjacent to the receptacle.
28. The device of claim 26 , wherein the plurality of openings are positioned along lateral sides of the device.
29. The device of claim 21 , wherein the test strip holder is sized and configured to receive a plurality of lateral flow test strips.
30. The device of claim 29 , wherein the receptacle comprises a plurality of receptacles corresponding to the plurality of lateral flow test strips, wherein each receptacle of the plurality of receptacles has a predetermined fluid volume selected to be applied to one corresponding lateral flow test strip of the plurality of lateral flow test strips.
31. The device of claim 21 , further comprising an absorbent material positioned in the overflow chamber and configured to absorb and hold the bodily fluids in excess of the predetermined fluid volume.
32. The device of claim 31 , wherein the absorbent material is a sponge or fabric.
33. The device of claim 21 , further comprising a transparent covering positioned over the test strip holder.
34. The device of claim 21 , further comprising a lip extending upward from an upper surface of the device along a peripheral edge of the device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/077,242 US20230098128A1 (en) | 2020-10-16 | 2022-12-08 | Devices and methods for lateral flow tests of bodily fluids |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063093011P | 2020-10-16 | 2020-10-16 | |
US17/495,034 US11567071B2 (en) | 2020-10-16 | 2021-10-06 | Devices and methods for lateral flow tests of bodily fluids |
US18/077,242 US20230098128A1 (en) | 2020-10-16 | 2022-12-08 | Devices and methods for lateral flow tests of bodily fluids |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/495,034 Continuation US11567071B2 (en) | 2020-10-16 | 2021-10-06 | Devices and methods for lateral flow tests of bodily fluids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230098128A1 true US20230098128A1 (en) | 2023-03-30 |
Family
ID=81186078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/495,034 Active US11567071B2 (en) | 2020-10-16 | 2021-10-06 | Devices and methods for lateral flow tests of bodily fluids |
US18/077,242 Pending US20230098128A1 (en) | 2020-10-16 | 2022-12-08 | Devices and methods for lateral flow tests of bodily fluids |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/495,034 Active US11567071B2 (en) | 2020-10-16 | 2021-10-06 | Devices and methods for lateral flow tests of bodily fluids |
Country Status (4)
Country | Link |
---|---|
US (2) | US11567071B2 (en) |
EP (1) | EP4221893A4 (en) |
CN (1) | CN116547074A (en) |
WO (1) | WO2022081605A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7270959B2 (en) * | 2001-07-25 | 2007-09-18 | Oakville Hong Kong Company Limited | Specimen collection container |
WO2005050167A2 (en) * | 2003-11-14 | 2005-06-02 | Oakville Hong Kong Co., Limited | Rapid sample collection and analysis device |
KR101324375B1 (en) | 2004-05-04 | 2013-11-01 | 바이엘 헬스케어 엘엘씨 | Mechanical cartridge with test strip fluid control features for use in a fluid analyte meter |
US20070224701A1 (en) | 2006-02-16 | 2007-09-27 | Becton, Dickinson And Company | Combination vertical and lateral flow immunoassay device |
US9839909B2 (en) * | 2006-07-28 | 2017-12-12 | Diagnostics For The Real World, Ltd. | Device, system and method for processing a sample |
CN102802797A (en) | 2009-04-21 | 2012-11-28 | 艾德万德克斯公司 | Multiplex analysis of cells, particles, and other analytes |
US9074920B2 (en) | 2009-06-03 | 2015-07-07 | Biometrix Ltd. | Apparatus and method for bedside collection of body fluids and automatic volume level monitoring |
GB0919159D0 (en) | 2009-11-02 | 2009-12-16 | Sec Dep For Environment Food A | Device and apparatus |
US20150010992A1 (en) | 2010-07-20 | 2015-01-08 | Quantrx Biomedical Corporation | Optical reader systems and lateral flow assays |
WO2013036913A1 (en) | 2011-09-08 | 2013-03-14 | Nexus Dx, Inc. | A multilevel analyte assay |
EP2807271B1 (en) | 2012-01-24 | 2018-08-22 | CD Diagnostics, Inc. | System for detecting infection in synovial fluid |
US10150843B2 (en) | 2015-03-17 | 2018-12-11 | Georgia-Pacific LLC | Process for liquefaction of lignocellulosic biomass |
US20210291182A1 (en) | 2016-11-17 | 2021-09-23 | BRISA Biotech, LLC | Multiplex Hybrid Microfluidics Analyte Detection Systems |
JP7250757B2 (en) | 2017-07-27 | 2023-04-03 | ベラックス バイオメディカル インコーポレイテッド | Sequential lateral flow device |
-
2021
- 2021-10-06 US US17/495,034 patent/US11567071B2/en active Active
- 2021-10-12 WO PCT/US2021/054623 patent/WO2022081605A1/en active Application Filing
- 2021-10-12 CN CN202180071013.6A patent/CN116547074A/en active Pending
- 2021-10-12 EP EP21880927.5A patent/EP4221893A4/en active Pending
-
2022
- 2022-12-08 US US18/077,242 patent/US20230098128A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116547074A (en) | 2023-08-04 |
EP4221893A1 (en) | 2023-08-09 |
WO2022081605A9 (en) | 2022-12-22 |
EP4221893A4 (en) | 2024-03-20 |
US11567071B2 (en) | 2023-01-31 |
WO2022081605A1 (en) | 2022-04-21 |
US20220120742A1 (en) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0712495B1 (en) | Lateral flow medical diagnostic assay device with sample extraction means | |
RU2657187C2 (en) | Quick test device and method | |
US20020085958A1 (en) | Apparatus for pretreating a sample containing an analyte | |
CN105683751B (en) | Device, system, method and kit for receiving a swab | |
US8062901B2 (en) | Devices and methods for sample collection and analysis | |
US20190059860A1 (en) | Stool specimen collecting, sampling and diagnosing means and methods thereof | |
JP4889498B2 (en) | High-speed sample analysis and storage device and method of use | |
US5268148A (en) | Saliva sampling device and sample adequacy system | |
US5169789A (en) | Device and method for self contained solid phase immunodiffusion assay | |
JP2018515785A (en) | Biological sample collection and analysis device and method of use thereof | |
WO1988004431A1 (en) | A device and method for self contained solid phase immunodiffusion assay | |
CZ20033357A3 (en) | Testing system | |
CN114585442A (en) | Detection device and reception device | |
US20200345286A1 (en) | Cassette device for quick test of diagnosis, method for detecting a ligand in a biological sample and kit | |
WO2006116917A2 (en) | Devices and methods for sample collection and analysis | |
US9632083B1 (en) | Rapid diagnostic test device by driven flow technology | |
US20100261157A1 (en) | Device and Method for Processing a Sample Contained in a Swab for Diagnostic Analysis | |
CN115902210A (en) | Device for detecting analyte in fluid sample | |
US9535061B1 (en) | Multi-functional rapid diagnostic test device | |
US11567071B2 (en) | Devices and methods for lateral flow tests of bodily fluids | |
JP2005520616A (en) | Method and apparatus for analyzing mammary fluid | |
CA2309504C (en) | Self-contained assay device and method | |
Kim et al. | Development of Rapid Diagnostic Technology for Pig Disease (2)-Rapid detection of PPE in the pig feces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FRESENIUS MEDICAL CARE HOLDINGS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERGMAN, ERIC DAVID;SLOAT, DANIEL LEWIS;LECLERC, JONATHAN FITZMAURICE;AND OTHERS;SIGNING DATES FROM 20211008 TO 20220114;REEL/FRAME:062018/0886 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: SENT TO CLASSIFICATION CONTRACTOR |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |